{"paper_id": "373d8d71ae999a1692066992feefb3cbed6161e0", "metadata": {"title": "Supplemental Data Promyelocytic Leukemia Zinc Finger Protein Regulates Interferon-Mediated Innate Immunity", "authors": [{"first": "Dakang", "middle": [], "last": "Xu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Michelle", "middle": [], "last": "Holko", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Anthony", "middle": ["J"], "last": "Sadler", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Bernadette", "middle": [], "last": "Scott", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Shigeki", "middle": [], "last": "Higashiyama", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Windy", "middle": [], "last": "Berkofsky-Fessler", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Melanie", "middle": ["J"], "last": "Mcconnell", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Paolo", "middle": [], "last": "Pandolfi", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Jonathan", "middle": ["D"], "last": "Licht", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Bryan", "middle": ["R G"], "last": "Williams", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [], "body_text": [{"text": "The sequences of the primers used for the PCR were as follows: http://tcoffee.vital-it.ch/cgi-bin/Tcoffee/tcoffee_cgi/index.cgi.", "cite_spans": [], "ref_spans": [], "section": "Quantitative Real-time PCR"}, {"text": "The sequences of the primers used for the PCR were as follows: Over-represented motifs were identified by using JASPAR (Bailey and Elkan, 1995; Stormo, 2000) . The top motifs were obtained from selected genes differentially induced by IFN\u03b1 treatment in RCC1 and ACHN cells by clustering the most statistically significant score.", "cite_spans": [{"start": 119, "end": 143, "text": "(Bailey and Elkan, 1995;", "ref_id": "BIBREF0"}, {"start": 144, "end": 157, "text": "Stormo, 2000)", "ref_id": "BIBREF4"}], "ref_spans": [], "section": "Chromatin Immunoprecipitation Assay"}, {"text": "The effect of PLZF on gene expression was analyzed using a U937T cell line stably transfected with a tet-regulated PLZF expression construct. Affymetrix U95A arrays were hybridized with RNA collected 0, 24 and 48 h following PLZF induction (tetracycline removal) in triplicate (McConnell et al., 2003) . Significantly induced genes were identified using SAM (Tusher et al., 2001 Figure 1D ). Crystallographic analysis of the BTB/POZ dimer defined several major structural features in previous studies (Melnick et al., 2000) . Our sequence alignment of the PLZF BTB/POZ domain with other BTB/POZ domains showed conserved residues (* or : in Figure S8 ), which were selected for mutational analysis. We predicted that mutations of the residues in this figure that disrupt dimerization would result in misfolded nonfunctional protein aggregates. Another prominent structure within the BTB/POZ domain is a charged-pocket region composed of some of the most conserved residues of the BTB/POZ sequence. ", "cite_spans": [{"start": 277, "end": 301, "text": "(McConnell et al., 2003)", "ref_id": "BIBREF1"}, {"start": 358, "end": 378, "text": "(Tusher et al., 2001", "ref_id": "BIBREF5"}, {"start": 501, "end": 523, "text": "(Melnick et al., 2000)", "ref_id": "BIBREF3"}], "ref_spans": [{"start": 379, "end": 388, "text": "Figure 1D", "ref_id": null}, {"start": 640, "end": 649, "text": "Figure S8", "ref_id": "FIGREF7"}], "section": "Table S2. PLZF Positively Regulates Immune Response Genes"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "The value of prior knowledge in discovering motifs with MEME", "authors": [{"first": "T", "middle": ["L"], "last": "Bailey", "suffix": ""}, {"first": "C", "middle": [], "last": "Elkan", "suffix": ""}], "year": 1995, "venue": "Proc Int Conf Intell Syst Mol Biol", "volume": "3", "issn": "", "pages": "21--29", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression", "authors": [{"first": "M", "middle": ["J"], "last": "Mcconnell", "suffix": ""}, {"first": "N", "middle": [], "last": "Chevallier", "suffix": ""}, {"first": "W", "middle": [], "last": "Berkofsky-Fessler", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Giltnane", "suffix": ""}, {"first": "R", "middle": ["B"], "last": "Malani", "suffix": ""}, {"first": "L", "middle": ["M"], "last": "Staudt", "suffix": ""}, {"first": "J", "middle": ["D"], "last": "Licht", "suffix": ""}], "year": 2003, "venue": "Mol Cell Biol", "volume": "23", "issn": "", "pages": "9375--9388", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "Highfrequency mutagenesis of human cells and characterization of a mutant unresponsive to both alpha and gamma interferons", "authors": [{"first": "R", "middle": [], "last": "Mckendry", "suffix": ""}, {"first": "J", "middle": [], "last": "John", "suffix": ""}, {"first": "D", "middle": [], "last": "Flavell", "suffix": ""}, {"first": "M", "middle": [], "last": "Muller", "suffix": ""}, {"first": "I", "middle": ["M"], "last": "Kerr", "suffix": ""}, {"first": "G", "middle": ["R"], "last": "Stark", "suffix": ""}], "year": 1991, "venue": "Proc Natl Acad Sci U S A", "volume": "88", "issn": "", "pages": "11455--11459", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions", "authors": [{"first": "A", "middle": [], "last": "Melnick", "suffix": ""}, {"first": "K", "middle": ["F"], "last": "Ahmad", "suffix": ""}, {"first": "S", "middle": [], "last": "Arai", "suffix": ""}, {"first": "A", "middle": [], "last": "Polinger", "suffix": ""}, {"first": "H", "middle": ["J"], "last": "Ball", "suffix": ""}, {"first": "K", "middle": ["L"], "last": "Borden", "suffix": ""}, {"first": "G", "middle": ["W"], "last": "Carlile", "suffix": ""}, {"first": "G", "middle": ["G"], "last": "Prive", "suffix": ""}, {"first": "J", "middle": ["D"], "last": "Licht", "suffix": ""}], "year": 2000, "venue": "Mol Cell Biol", "volume": "20", "issn": "", "pages": "6550--6567", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "DNA binding sites: representation and discovery", "authors": [{"first": "G", "middle": ["D"], "last": "Stormo", "suffix": ""}], "year": 2000, "venue": "Bioinformatics", "volume": "16", "issn": "", "pages": "16--23", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Significance analysis of microarrays applied to the ionizing radiation response", "authors": [{"first": "V", "middle": ["G"], "last": "Tusher", "suffix": ""}, {"first": "R", "middle": [], "last": "Tibshirani", "suffix": ""}, {"first": "Chu", "middle": [], "last": "", "suffix": ""}, {"first": "G", "middle": [], "last": "", "suffix": ""}], "year": 2001, "venue": "Proc Natl Acad Sci U S A", "volume": "98", "issn": "", "pages": "5116--5121", "other_ids": {}}}, "ref_entries": {"FIGREF1": {"text": "categories enriched in the clusters together (all) and individually (1-7) are listed. All characteristics with an EASE score <0.130 are included. None met this criterion for sets 2 and 3.(LH, number of hits in the set of genes; LT, total number of genes in the set; PH, number of hits in the total gene list; PT, number of genes in the total gene list.) Two RCC cell lines were treated with IFN-\u03b1 at half-logarithmic doses between 10 and 5000 IU/ml for 96 h. Human IFN-\u03b1-2b was added at 2-fold dilutions beginning with 2.5 ng/well, and incubated for 16 h. Encephalomyocarditis virus diluted in medium was added to pretreated cells at a final concentration of 100 TCID 50 /well. Cells were fixed and stained with crystal violet 72 h postinfection, and the lowest dose required to protect 50% of the cells was determined as 1 unit (U).", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Putative binding sites for transcription factors in the Rsad2, Ifit1 and Ifit2 promoters, as predicted using the TRANSFAC program.", "latex": null, "type": "figure"}, "FIGREF3": {"text": "PLZF expression in mouse embryonic fibroblasts (MEFs). Protein expression levels of PLZF are shown in WT MEFs, Zbtb16 -/-MEFs and B cell subsets that were sorted from spleen as a negative control.", "latex": null, "type": "figure"}, "FIGREF4": {"text": "ZBTB16 expression in immune cells from the human microarray database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=nuccore&itool=toolbar). ZBTB16, which encodes the transcription factor PLZF, has higher expression in NK cells than in other cells (top panel). ZBTB16 (PLZF) also has higher expression in NKT and NK cells in mouse immune cells (http://www.immgen.org/index_content.html) (bottom panel).", "latex": null, "type": "figure"}, "FIGREF5": {"text": "PLZF acts at the transcriptional level. Pre-treatment with actinomycin D at a final concentration of 5 \u00b5g/ml. PLZF-inducible U937T cells were treated with 1,000 IU/ml IFN\u03b1 in the presence and absence of PLZF expression (24 h tetracycline withdrawal). RNA was extracted and mRNA of ISG expression was measured using real time RT-PCR analysis.", "latex": null, "type": "figure"}, "FIGREF6": {"text": "Over-expression of PLZF in RCC1 cells induces Rsad2 and Ifit2 promoter activity, but not Ifit1 promoter activity. Cells were co-transfected with a PLZF expression plasmid and Rsad2-Luc, Ifit1-Luc or Ifit2-Luc promoter reporter constructs respectively, followed by treatment with IFN\u03b1. The luciferase values were obtained in at least three independent experiments. (The Rsad2, Ifit2 and Ifit1 promoters contain an ISRE binding site, but the Ifit1 promoter lacks a PLZF binding site.) Chromatin immunoprecipitation performed in ACHN and RCC1 cells. Cells were treated with IFN\u03b1 (1,000 U/ml for 6 or 24 h), then immunoprecipitated with an anti-PLZF antibody. Promoters of Rsad2, Ifit2 and Ifi15 were amplified from the immunoprecipitated chromatin using SYBR Green quantitative RT-PCR. Data was normalized to the 10% input and FLAG antibody samples.", "latex": null, "type": "figure"}, "FIGREF7": {"text": "Schematic representation of the PLZF transcription factor (at top) with the amino acid sequence of the BTB domain aligned with other BTB domains showing conserved residues (* or :) identified by the Conserved Domain Database (CDD) and TCoffee (below). Residues within the PLZF BTB domain selected for mutational analysis are numbered (see also Figures S9 and S10).", "latex": null, "type": "figure"}, "FIGREF8": {"text": "PLZF protein sequence was run by the NetPhos 2.0 server program for predictions of serine, threonine and tyrosine phosphorylation sites in eukaryotic proteins. The figure shows higher scores of threonine and serine phosphorylation sites in the BTB domain of PLZF. Kinasespecific phosphorylation predictions are available at: http://www.cbs.dtu.dk/services/NetPhosK/. Contribution of the PLZF BTB/POZ domain to transcriptional regulation of ISGs.", "latex": null, "type": "figure"}, "FIGREF9": {"text": "Promoter activity analysis showing the response of ISG Rsad2 in 2fTGH and mutant cells, U3A (Stat1), U4A (JAK1), U5A (IFNAR2) and U6A (Stat2) (McKendry et al., 1991). Cells were transfected with Rsad2-Luc promoter reporter constructs with pRL-TK Vector as the internal control of transfection efficiency, following treatment with IFN\u03b1. The luciferase values were obtained by calculating the ratio of the activity of the experimental reporter normalized to the activity of the internal control.", "latex": null, "type": "figure"}, "FIGREF10": {"text": "Hela cells transiently transfected with FLAG-PLZF for 24 h, followed by IFN\u03b1 treatment for 2-3 h. The cell lysates were prepared for immunoprecipitation (IP) with the anti-FLAG antibody and subjected to immunoblot (IB) analysis by using the HDAC1 antibody, or anti-FLAG antibody, as indicted.", "latex": null, "type": "figure"}, "FIGREF11": {"text": "PLZF interacts with PML and HDAC1. Hela cells were transiently transfected with wild-type (WT) FLAG-PLZF or various mutant PLZF expression plasmids, followed by IFN\u03b1 treatment, immunoprecipitated with the anti-FLAG antibody and immunoblotted with a PML, HDAC1 or FLAG antibody, as indicated.", "latex": null, "type": "figure"}, "FIGREF12": {"text": "IFN\u03b1 did not induce an increase in the number of PML NBs during 0-6 h IFN\u03b1 treatment. Hela cells were left untreated or treated with 500 IU/ml IFN\u03b1 for 3 and 6 h, and then immunostained with PML antibody. The number of PML NBs per nucleus detected by PML antibody was counted on sections taken through the entire cell nucleus. 100 cells were counted for each treatment.", "latex": null, "type": "figure"}, "TABREF0": {"text": "The web programs used for the bioinformatic analyses were:EASE Functional Annotation Tool Suite: http://david.niaid.nih.gov/david/ease.htm; MatInspector (Genomatix Suite): http://www.genomatix.de/company/index.html; MEME: http://meme.sdsc.edu/meme/intro.html; JASPAR: http://jaspar.genereg.net); Conserved Domain Database: http://www.ncbi.nlm.nih.gov/sites/entrez?db=cdd; Evaluating and Manipulating Multiple Alignments of Protein Sequences:", "latex": null, "type": "table"}, "TABREF1": {"text": "Over-represented Promoter Motifs From Genes Differentially Induced by IFN\u03b1", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>\u00a0</td><td>P value from randomizing </td></tr><tr><td>Motif </td><td>Raw score </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>hs_upstream </td></tr><tr><td>IRF1 cluster </td><td>18.1 </td><td>0.0 </td></tr><tr><td>IRF2 cluster </td><td>12.2 </td><td>0.0 </td></tr><tr><td>PLZF motif (broad-complex Zn-\n</td><td>7.41 </td><td>0.0 </td></tr><tr><td>finger, C2H2 motif) </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>NHLH1 bHLH </td><td>5.89 </td><td>0.0070 </td></tr><tr><td>MNB1A Zn-finger </td><td>5.53 </td><td>0.0040 </td></tr><tr><td>Dof3 Zn-finger </td><td>4.91 </td><td>0.0020 </td></tr><tr><td>E74A Ets </td><td>4.83 </td><td>0.01 </td></tr><tr><td>PBF Zn-finger </td><td>4.82 </td><td>0.0020 </td></tr><tr><td>c-Ets Ets </td><td>3.83 </td><td>0.0070 </td></tr></table></body></html>"}, "TABREF2": {"text": "). Genes upregulated 24 or 48 h after PLZF induction were analyzed for over-represented gene categories using EASE (http://david.niaid.nih.gov/david/ease.htm). The top twenty enriched categories include several immune response pathways.", "latex": null, "type": "table"}, "TABREF3": {"text": "Genes Induced by PLZF", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Systematic </td><td>0 </td><td>24 </td><td>48 Product\n</td></tr><tr><td>36243_at </td><td>1.0 </td><td>2.5 </td><td>3.2 hypothetical protein\n</td></tr><tr><td>1787_at </td><td>1.3 </td><td>8.2 </td><td>10.1 cyclin-dependent kinase inhibitor 1C\n</td></tr><tr><td>33304_at </td><td>0.9 </td><td>2.2 </td><td>4.2 interferon stimulated gene (20kD)\n</td></tr><tr><td>35211_at </td><td>1.4 </td><td>6.6 </td><td>3.1 protein phosphatase 2 (formerly 2A), regulatory subunit B'' (PR\n</td></tr><tr><td>1520_s_at </td><td>0.9 </td><td>4.6 </td><td>6.6 endothelin 1\n</td></tr><tr><td>39775_at </td><td>1.0 </td><td>2.3 </td><td>2.6 complement component 1 inhibitor\n</td></tr><tr><td>37600_at </td><td>1.0 </td><td>2.4 </td><td>4.8 extracellular matrix protein 1\n</td></tr><tr><td>38064_at </td><td>0.9 </td><td>2.7 </td><td>2.9 major vault protein\n</td></tr><tr><td>669_s_at </td><td>1.0 </td><td>2.8 </td><td>4.0 interferon regulatory factor 1\n</td></tr><tr><td>36638_at </td><td>1.0 </td><td>2.7 </td><td>3.3 connective tissue growth factor\n</td></tr><tr><td>34476_r_at </td><td>1.2 </td><td>4.6 </td><td>3.4 epiregulin precursor\n</td></tr><tr><td>41031_at </td><td>1.5 </td><td>4.5 </td><td>2.6 osteomodulin\n</td></tr><tr><td>39850_at </td><td>1.1 </td><td>8.3 </td><td>10.2 ankyrin 2, isoform 1\n</td></tr><tr><td>1852_at </td><td>1.1 </td><td>2.7 </td><td>2.9 tumor necrosis factor (cachectin)\n</td></tr><tr><td>38540_at </td><td>1.0 </td><td>6.0 </td><td>2.0 muscle RAS oncogene homolog\n</td></tr><tr><td>1993_s_at </td><td>1.0 </td><td>2.1 </td><td>2.5 breast cancer 1, early onset\n</td></tr><tr><td>281_s_at </td><td>1.9 </td><td>3.3 </td><td>4.5 protein phosphatase 3 (formerly 2B), catalytic subunit, alpha iso\n</td></tr><tr><td>33896_at </td><td>1.7 </td><td>9.6 </td><td>9.2 E1A binding protein p300\n</td></tr><tr><td>1082_at </td><td>1.1 </td><td>3.1 </td><td>3.5 phospholipase C, gamma 1 (formerly subtype 148)\n</td></tr><tr><td>1036_at </td><td>1.0 </td><td>5.9 </td><td>3.3 Interleukin 15\n</td></tr><tr><td>36412_s_at </td><td>1.0 </td><td>2.1 </td><td>2.2 interferon regulatory factor 7 isoform a\n</td></tr><tr><td>32068_at </td><td>1.0 </td><td>2.6 </td><td>2.3 complement component 3a receptor 1\n</td></tr><tr><td>31945_s_at </td><td>2.1 </td><td>3.7 </td><td>2.0 SH2 domain protein 1A, Duncan's disease (lymphoproliferative </td></tr><tr><td>40663_at </td><td>1.3 </td><td>2.7 </td><td>4.6 RALBP1 associated Eps domain containing 2\n</td></tr><tr><td>38584_at </td><td>1.0 </td><td>2.6 </td><td>3.3 interferon-induced protein with tetratricopeptide repeats 4\n</td></tr><tr><td>2031_s_at </td><td>1.0 </td><td>3.8 </td><td>5.6 cyclin-dependent kinase inhibitor 1A (p21, Cip1)\n</td></tr><tr><td>38388_at </td><td>1.0 </td><td>4.9 </td><td>10.1 2',5'-oligoadenylate synthetase 1, isoform E18\n</td></tr><tr><td>34334_at </td><td>1.0 </td><td>5.6 </td><td>2.6 ephrin-B2\n</td></tr><tr><td>38378_at </td><td>1.0 </td><td>15.7 </td><td>26.8 CD53 antigen\n</td></tr><tr><td>34478_at </td><td>1.1 </td><td>5.3 </td><td>5.1 RAB11B, member of RAS oncogene family\n</td></tr><tr><td>34623_at </td><td>0.9 </td><td>2.2 </td><td>2.1 defensin, alpha 5, Paneth cell-specific\n</td></tr></table></body></html>"}, "TABREF4": {"text": "PLZF-Responsive ISGsU937T:PLZF45 cells were analyzed for ISG expression following IFN treatment in the presence and absence of PLZF expression using the ISG array. PLZF-regulated genes are defined as induced at least 1.5-fold in PLZF alone, or 1.5-fold higher in PLZF and IFN as compared to the same time point of IFN treatment alone. The top 50 PLZF-regulated ISGs are listed. Expression of the highlighted genes was verified using Sybr Green real time RT-PCR (see", "latex": null, "type": "table"}, "TABREF6": {"text": "Pathways Enriched in PLZF-Responsive Gene Clusters", "latex": null, "type": "table", "html": "<html><body><table><tr><td>set </td><td>System </td><td>Category </td><td>LH </td><td>LT </td><td>PH </td><td>PT </td><td>EASE Score </td><td>Fisher </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>G-protein </td><td>coupled receptor </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Exact </td></tr><tr><td>all </td><td>\u00a0</td><td>protein signaling pathway 12 </td><td>134 </td><td>16 </td><td>411 </td><td>0.003 </td><td>0.0005 </td></tr><tr><td>all </td><td>molecular_function biological_process biological_process </td><td>enzyme regulator activity 12 </td><td>124 </td><td>21 </td><td>404 </td><td>0.026 </td><td>0.009 </td></tr><tr><td>all </td><td>neurophysiological process 8 </td><td>134 </td><td>13 </td><td>411 </td><td>0.087 </td><td>0.028 </td></tr><tr><td>all </td><td>\u00a0</td><td>cell proliferation </td><td>25 </td><td>134 </td><td>59 </td><td>411 </td><td>0.094 </td><td>0.059 </td></tr><tr><td>all </td><td>biological_process molecular_function biological_process </td><td>growth factor activity 7 </td><td>124 </td><td>12 </td><td>404 </td><td>0.122 </td><td>0.041 </td></tr><tr><td>all </td><td>intracellular signaling cascade 18 </td><td>134 </td><td>41 </td><td>411 </td><td>0.128 </td><td>0.075 </td></tr><tr><td>all </td><td>\u00a0</td><td>endopeptidase 5 </td><td>124 </td><td>7 </td><td>404 </td><td>0.130 </td><td>0.031 </td></tr><tr><td>1 </td><td>molecular_function cellular_component </td><td>serine-type inhibitor activity cytoskeleton organismal process </td><td>3 </td><td>8 </td><td>8 </td><td>112 </td><td>0.079 </td><td>0.0115 </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>physiological </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>4 </td><td>biological_process biological_process biological_process biological_process </td><td>6 </td><td>11 </td><td>37 </td><td>134 </td><td>0.104 </td><td>0.0467 </td></tr><tr><td>4 </td><td>signal transduction </td><td>20 </td><td>39 </td><td>44 </td><td>134 </td><td>0.008 </td><td>0.004 </td></tr><tr><td>4 </td><td>intracellular signaling cascade 11 </td><td>39 </td><td>18 </td><td>134 </td><td>0.009 </td><td>0.002 </td></tr><tr><td>4 </td><td>cell communication 21 </td><td>39 </td><td>50 </td><td>134 </td><td>0.018 </td><td>0.010 </td></tr><tr><td>4 </td><td>\u00a0</td><td>cellular process </td><td>29 </td><td>39 </td><td>81 </td><td>134 </td><td>0.036 </td><td>0.026 </td></tr><tr><td>4 </td><td>biological_process cellular_component molecular_function </td><td>membrane </td><td>15 </td><td>30 </td><td>38 </td><td>112 </td><td>0.049 </td><td>0.027 </td></tr><tr><td>4 </td><td>enzyme regulator activity 7 </td><td>34 </td><td>12 </td><td>124 </td><td>0.062 </td><td>0.018 </td></tr><tr><td>4 </td><td>\u00a0</td><td>plasma membrane </td><td>10 </td><td>30 </td><td>22 </td><td>112 </td><td>0.067 </td><td>0.029 </td></tr><tr><td>5 </td><td>cellular_component cellular_component </td><td>\u00a0</td><td>12 </td><td>30 </td><td>30 </td><td>112 </td><td>0.093 </td><td>0.050 </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>endopeptidase </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>5 </td><td>molecular_function molecular_function </td><td>cytoplasm serine-type inhibitor activity </td><td>4 </td><td>34 </td><td>5 </td><td>124 </td><td>0.117 </td><td>0.020 </td></tr><tr><td>5 </td><td>protease inhibitor activity 4 </td><td>34 </td><td>5 </td><td>124 </td><td>0.117 </td><td>0.020 </td></tr><tr><td>5 </td><td>\u00a0</td><td>\u00a0</td><td>inhibitor 4 </td><td>34 </td><td>5 </td><td>124 </td><td>0.117 </td><td>0.020 </td></tr><tr><td>5 </td><td>molecular_function cellular_component molecular_function cellular_component biological_process </td><td>endopeptidase activity extracellular space </td><td>4 </td><td>12 </td><td>9 </td><td>112 </td><td>0.043 </td><td>0.007 </td></tr><tr><td>5 </td><td>binding </td><td>10 </td><td>11 </td><td>79 </td><td>124 </td><td>0.066 </td><td>0.044 </td></tr><tr><td>5 </td><td>extracellular </td><td>4 </td><td>12 </td><td>13 </td><td>112 </td><td>0.117 </td><td>0.033 </td></tr><tr><td>5 </td><td>\u00a0</td><td>3 </td><td>7 </td><td>15 </td><td>134 </td><td>0.135 </td><td>0.031 </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>cell cycle nucleobase, nucleotide and metabolism </td><td>nucleoside, nucleic acid </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>5 </td><td>\u00a0</td><td>4 </td><td>7 </td><td>33 </td><td>134 </td><td>0.159 </td><td>0.062 </td></tr><tr><td>5 </td><td>biological_process biological_process molecular_function biological_process </td><td>G-protein coupled receptor protein signaling pathway 12 </td><td>134 </td><td>16 </td><td>411 </td><td>0.003 </td><td>0.0005 </td></tr><tr><td>5 </td><td>enzyme regulator activity 12 </td><td>124 </td><td>21 </td><td>404 </td><td>0.026 </td><td>0.009 </td></tr><tr><td>6 </td><td>neurophysiological process 8 </td><td>134 </td><td>13 </td><td>411 </td><td>0.087 </td><td>0.028 </td></tr><tr><td>6 </td><td>\u00a0</td><td>cell proliferation </td><td>25 </td><td>134 </td><td>59 </td><td>411 </td><td>0.094 </td><td>0.059 </td></tr><tr><td>6 </td><td>biological_process molecular_function biological_process </td><td>growth factor activity 7 </td><td>124 </td><td>12 </td><td>404 </td><td>0.122 </td><td>0.041 </td></tr><tr><td>7 </td><td>intracellular signaling cascade 18 </td><td>134 </td><td>41 </td><td>411 </td><td>0.128 </td><td>0.075 </td></tr><tr><td>7 </td><td>molecular_function </td><td>serine-type inhibitor activity </td><td>endopeptidase 5 </td><td>124 </td><td>7 </td><td>404 </td><td>0.130 </td><td>0.031 </td></tr></table></body></html>"}}, "back_matter": []}